Arrhythmogenic Cardiomyopathy in 2018-2019: ARVC/ALVC or Both?
Richard G Bennett1, Haris M Haqqani2, Antonio Berruezo3
1Bristol Heart Institute, Bristol, UK.
Insights
Arrhythmogenic cardiomyopathy (ACM) is a progressive heart muscle disease characterized by fibrofatty infiltration, often hereditary. Diagnosis is challenging, requiring integrated criteria, and management focuses on preventing sudden cardiac death and heart failure.
Area of Science:
- Cardiology
- Genetics
- Pathology
Background:
- Arrhythmogenic cardiomyopathy (ACM) is a progressive, hereditary heart muscle disease characterized by fibrofatty infiltration of the ventricles.
- While classically involving the right ventricle (RV), left or biventricular involvement is now recognized, often linked to genetic mutations affecting intercalated discs.
Purpose of the Study:
- To provide a comprehensive review of the current understanding of arrhythmogenic cardiomyopathy (ACM).
- To outline the pathogenesis, diagnostic challenges, and contemporary treatment strategies for ACM.
Main Methods:
- Review of established Taskforce criteria incorporating electrical, structural, tissue, and genetic evaluations.
- Discussion of diagnostic challenges including variable expressivity, incomplete penetrance, and differentiation from other cardiac conditions.
- Overview of current therapeutic strategies, including lifestyle modifications, pharmacotherapy, device implantation, and catheter ablation.
Main Results:
- ACM diagnosis is complex, relying on integrated criteria due to variable presentation and potential for electrical abnormalities preceding structural changes.
- Genetic testing identifies pathogenic mutations in approximately 50% of patients, highlighting the need for genotype-phenotype correlation.
- Catheter ablation is increasingly recognized as a primary treatment for recurrent ventricular arrhythmias in ACM.
Conclusions:
- ACM requires a multidisciplinary approach for accurate diagnosis and effective management.
- Early identification and risk stratification are crucial for preventing adverse outcomes such as sudden cardiac death and heart failure.
- Advances in genetic testing and ablation techniques are improving the management of ACM patients.
Abstract:
Arrhythmogenic cardiomyopathy (ACM) is now commonly used to describe any form of non-hypertrophic, progressive cardiomyopathy characterised by fibrofatty infiltration of the ventricular myocardium. Right ventricular (RV) involvement refers to the classical arrhythmogenic right ventricular cardiomyopathy, but left ventricular, or bi-ventricular involvement are now recognised. ACM is mostly hereditary and associated with mutations in genes encoding proteins of the intercalated disc. ACM classically manifests as ventricular arrhythmias, and sudden death may be the first presentation of the disease. Heart failure is seen with advanced stages of the disease. Diagnosis can be challenging due to variable expressivity and incomplete penetrance, and is guided by established Taskforce criteria that incorporate electrical features (12-lead electrocardiography (ECG), features of ventricular arrhythmias), structural features (on imaging via echo and cardiac magnetic resonance imaging [MRI]), tissue characteristics (via biopsy), and familial/genetic evaluation. Electrical abnormalities may precede structural alterations, which also make diagnosis challenging, especially in differentiating ACM from other conditions such as benign right ventricular arrhythmias, channelopathies such as Brugada, or the Athlete's Heart. Genetic testing is critical in identifying familial mutations and initiating cascade testing, but finds a pathogenic mutation in only ∼50% of patients. Some critical genotype-phenotype correlations do exist and may help guide risk stratification and give clues to disease progression. Therapeutic strategies include restriction from high endurance and competitive sports, ß-blockers, antiarrhythmic drugs, heart failure medications, implantable cardioverter-defibrillators and combined endocardial/epicardial catheter ablation. Ablation has emerged as the treatment of choice for recurrent ventricular arrhythmias in ACM. This state-of-the-art review outlines the pathogenesis, diagnosis and treatment of ACM in the contemporary era.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
SI Units: 2019 Redefinition
A standard set of units has been defined...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification


